Global Stem Cells Group Announces the Launch of a New Bone Marrow Harvesting Kit
The Global Stem Cells Group has announced the launch of a new bone marrow harvesting kit in response to a request for effective and accessible solutions to regenerative medicine procedures
Bone marrow is a spongy tissue that is located inside most large bones – it is essential for generating red blood cells (erythrocytes), white blood cells (leukocytes) and platelets (thrombocytes), using a bone marrow aspirate needle to collect the aspirate can help physicians perform different regenerative treatments especially in osteomioarticular conditions.
Increased Stem and Progenitor Cell Concentrations in Marrow Aspiration
According to the company, the new kit for processing and extraction of pure bone marrow has demonstrated its ability to increase stem and progenitor cell concentrations in marrow aspiration compared to traditional needles. It further adds that the device overcomes the limitations of traditional needles that restrict the amount of peripheral blood that would otherwise have been aspirated by forcing aspiration flow through side ports rather than from an open cannula. This setup has been a major issue with traditional needles and often led to the extraction of excessive amounts of bone marrow as well as impure marrow.
“Cellgenic plans with this new device to position itself as a leader in the development and manufacture of single-use medical devices for a number of medical specialties, we have developed a new bone marrow aspiration and biopsy needle that is manual, sterile and disposable, allowing precise procedures to be performed” said Benito Novas C.E.O of Global Stem Cells group
The new system offers the facility for doctors to reposition the needle more precisely at different access points. Precision is vital when trying to access bone marrow from specific sections of the bone.
According to Benito Novas, CEO of Global Stem Cells Group, the product will be launched at a press conference this September in Istanbul, Turkey within the framework of the World Congress of Regenerative Medicine. Additionally, it will be available at retail for doctors and distributors worldwide from October 2022
Buyers will undergo an orientation to use the new kit. It is easy to work with and many are expected to start using it as soon as they purchase it. The stem cells group will offer all the necessary training and support for the doctors during training and thereafter to ensure that the medical practitioners enjoy the full benefits of the device.
Global Stem Cells Group has been on the frontline in offering quality devices for stem cell procedures. It aims to make procedures as simple, risk-free, and efficient as possible for the maximum benefit of patients.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Releases
Global Stem Cells Group Signs Ramzan Ali Stem Cell Center as Their Preferred Dealers in Pakistan
Global Stem Cells Group has announced the signing of an exclusive contract with Ramzan Ali Stem Cell Center to expand the company’s service for Patients, doctors and product lines in Pakistan
GSCG and Ramzan Ali Stem Cell Center have signed an exclusivity agreement for 5 years to enhance GSCG’s services in Pakistan that entails multiple locations for patient treatment, 4 annual training dates for doctors and an annual congress to raise awareness of the benefits of cellular medicine in the country, as well as access to entire global stem cells group line of cellular products.
The GSCG and Ramzan Ali Stem cell center alliance aims to introduce state-of-the-art medical technology. It’s a merger that will cover medical training in 5 cities in the country that will provide essential treatment. The contract covers the launch of the cellular products that Global manufactures and distributes. It includes the Cellgenic line of Exosomes in lyophilized and liquid versions.
This partnership seeks to expand the brand and create centers of excellence in cell therapy to meet the demand in the Asian and Middle Eastern markets. Global Stem Cells Group is rapidly expanding its operations globally as it seeks to dominate the lucrative health industry of regenerative medicine. The organization is merging with healthcare providers majoring in regenerative medicine with at least five years of experience in the healthcare sector to achieve its expansion plans.
Ramzan Ali Stem Cell Center is an exclusive regenerative medicine service provider that treats chronic conditions. degenerative diseases. and injuries via stern cell therapy in Pakistan. The organization has a team of highly trained specialists of licensed medical doctors, and post-graduate physicians. and surgeons.
According to Benito Novas. the Managing Director of Global Stem Cells Group. the partnership aligns with the company’s long-term goals and expansion plan. “Our top objective is to make the benefits of regenerative medicine a reality for doctors and patients worldwide. The business continues to grow and position itself as a market leader.” He adds.
This new merger will incorporate state-of-the-art stem cell practices and procedures. These measures will ensure that patients access efficient and affordable options when seeking reliable solutions.
Prof. Dr. Mahmood Shaukat, Head of Ramzan Ali Stem Cell Centre welcomed the alliance. He said his organization is proud to be part of the GSCG growing family. It’s a collaboration that will see them access stem cell equipment, physician training. certification, and Stem Cell Training from a group with a remarkable history and great international renown.
According to Mr. Syed Asad Ali Ashraf, Managing Partner of Ramzan Ali Syed Hospital, the union aims to dominate the Asian and Middle East markets. “We want to bring all GSCG’s business lines to Pakistan by adopting stem cell training, certification, products, production, patient care, and equipment:’ He adds. It’s an alliance that will enable the institution to expand to five cities in Pakistan. The move will ensure state-of-the-art and affordable regenerative medical care in the country.
Global Stem Cells Group has taken the lead in the health sector with the current advancement in technological sciences. It’s a merger that aims to deliver the latest regenerative medicine majoring in biotechnology, stem cell, and genome to the health care industry in Pakistan.
- Published in Press Releases
ISSCA Opening of Uccle, Belgium Center with GCell & Stem Cell Training
After several months of organizing and developing a location, the Global Stem Cells Group has finalized the construction of a laboratory and regenerative medicine research center in Uccle, Belgium.
This facility serves both as a regenerative medicine treatment and research center, but also as a plastic surgery clinic. In addition to this, one of the primary goals of the Center is to serve as a place for the fostering of knowledge and experience regarding the different products and equipment required for the application of cellular therapies. As part of the inaugural ceremony a group of physicians were trained in the setup and use of the various regenerative medicine protocols and application process of these cells into the patients.
This center is a push into Europe for the Global Stem Cells Group. As the science advances, newer and more advanced therapies and technologies are being developed and released into the market with each passing month.
With the European Union being one of the largest consumer markets in the world, the finalization of a brick-and-mortar location in Brussels, Belgium is one that will mean great things for the Global Stem Cells Group, and the presence and proliferation of regenerative medicine throughout Europe and the world.
“This was a wonderful opportunity that we could have. It goes to show that even during this pandemic, the medical community is one that is still going strong. We’re still rallying together to look for new breakthroughs, and come up with the most beneficial treatment options for patients,” Said Benito Novas, founder of the International Society for Stem Cell Applications, “In addition to this, it also provides an excellent platform for the distribution of regenerative medicine therapies and equipment, including the revolutionary new GCell Machine,”
Indeed, the inaugural training at the Stem Cell Center in Uccle, Belgium was one that covered both of the more traditional methods of stem cell isolation and application– adipose and bone-marrow derived autologous cells, but this training was also one of the first in which the company had the ability to demonstrate the novel GCell Machine. Using a precise system of blades and filters, it is able to process a stem cell sample from adipose tissue in less than half of the time that it would take a physician to do so through traditional means.
This allows the patient to be more comfortable throughout the shorter procedure, as less anesthesia is also required than when operating under traditional means. The GCell is a minimally invasive, portable machine that allows physicians to fully unlock the potential of regenerative medicine as a component in their practice. Using their global network of distributors and licensed vendors, Global Stem Cells Group is working fervently to ensure no interruption in the global availability of the most cutting-edge regenerative medicine products.
- Published in Press Releases
How Cellgenic MSCs Revolutionize Regenerative Medicine
Stem Cells are revolutionizing the field of regenerative medicine, due to their intelligence. Once administered into the patient, they are able to identify and target areas of disease and damage. Adimarket’s Mesenchymal Stem Cell Product excretes growth factors, cytokines, and proteins, which all play a key role in the regeneration of tissue. Their anti-inflammatory and immunomodulatory properties mean that it is difficult for them to be rejected by the body. Additionally, they increase blood flow to the vital organs which need it the most.
Many proprietors of MSC products will claim that it is not necessarily important to have a high ratio of viable cells. They claim that it does not matter how many cells are ‘not viable’, or dead, so long as there is a high enough number of viable cells– however, current research has shown that this is not the case. These dead cells are detectable by the immune system, and it is believed that they can create an inflammatory response within the body at the treatment area, which would lower the effectiveness of the regenerative medicine treatments.
This bending of the science is harmful to our industry, which is why knowledgeable purveyors put one thing above all else– consistency. Our cellular concentrations are the same throughout each batch, and we make sure that there is a high ratio of viable cells. All of our samples are independently verified by a third party laboratory, and have been selected for their phenotypic and genotypic profile, characterized for optimum growth and stability. When the proper care is taken, Mesenchymal Stem Cell products have been identified as having the highest output of growth factors and stem cell factors among the current standards of care– as well as properties of angiogenesis, immunomodulation, and the potential for endogenous repair.
Cellgenic has been working for over a decade, constantly reinventing itself and reinforcing the products that we offer with the latest advancements in the field of regenerative medicine. We take every painstaking measure possible to ensure that the cellular samples that our customers use to treat their patients are second to none– this includes the consistent concentrations of our sample, which are the same throughout ensuring that every patient gets the same treatment. We offer the product in 10 million or 30 million live total nucleated cells, where other fabricators would have the same number of total cells. We ensure that every single product that we send out has been tested for low amounts of annexin, which is a cellular protein which serves as a marker for cell death.
All our Mesenchymal Stem Cell products come in 1cc vials cryogenically preserved– they are shipped overnight within the United States, conveniently delivered to your door in the morning. For use, the product is passively thawed between the palms of your hands– and ready to use when your patients are. MSC 10 contains 10 million live cells and is recommended for a single joint, or a small area. However, the MSC pure pro has 30 million live cells,and can be used for larger applications, or for up to three joints in the same patient at the same time.
If you are interested in finding out more about Cellgenic MSCs, you can send an eMail to firstname.lastname@example.org
- Published in Corporate News / Blog